Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab

• Published in: Drugs in R&D Vol. 17; no. 4; pp. 607 - 613
• Main Author: Ehrenpreis, Eli D.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2017; Springer Nature B.V
• Subjects: Antibodies; Antibodies - blood; Area Under Curve; Biological products; Body mass index; Drug dosages; Drug efficacy; Enzymes; Half-Life; Healthy Volunteers; Humans; Immunoglobulins; Immunotherapy; Infliximab - administration & dosage; Infliximab - blood; Infliximab - immunology; Injections, Intravenous; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Clearance Rate; Models, Biological; Monoclonal antibodies; Nonlinear Dynamics; Original; Original Research Article; Patients; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Regression analysis; Single-Blind Method; TNF inhibitors; Tumor necrosis factor-TNF; United States > US
• ISSN: 1174-5886; 1179-6901; 1179-6901
• DOI: 10.1007/s40268-017-0211-y

Background Infliximab pharmacokinetic studies have been performed in patients receiving chronic infliximab therapy. In these patients, infliximab antidrug antibodies (ADAs) increase infliximab clearance and decrease serum levels and drug efficacy. Objective This study analyzed the pharmacokinetic effect of infliximab ADAs in healthy subjects receiving a single dose of intravenous infliximab. Methods Data were obtained from a single-blind, parallel-group, single-dose study of healthy subjects receiving 5 mg/kg of intravenous SB2 (infliximab biosimilar), EU-sourced Remicade (EU-IFX) or US-sourced Remicade (US-IFX). Serum infliximab was measured at 1, 2, 3, 6, 12, 24, 48, and 72 h and at 5, 7, 14, 21, 28, 42, 56, and 70 days after administration. ADAs were measured pre-dose and at 29 and 71 days. Data from the first ten subjects randomized to each treatment arm were utilized for this study. A two-compartment model of the serum infliximab vs. time curve was developed using nonlinear regression. Results At 10 weeks, 11 subjects (37%) developed ADAs. ADAs were detected in four subjects after SB2, one subject after EU-IFX, and six subjects after US-IFX infusion. Of these, neutralizing antibodies occurred in one subject after SB2, in no subjects after EU-IFX, and in three subjects after US-IFX infusion. Infliximab clearance was increased in subjects with ADAs vs. those without ADAs (12.89 ± 2.69 vs. 9.90 ± 1.74 ml/h; p  < 0.0005). The elimination half-time was shorter in subjects with ADAs (282.4 ± 56.4 vs. 343.3 ± 61.9 h; p  < 0.01). Serum infliximab measured at 8 weeks correlated closely with infliximab clearance ( R 2  = 0.5494; p  < 0.0001). Conclusion ADAs are common in healthy subjects after a single intravenous dose of infliximab and result in faster infliximab clearance, shorter elimination time, and lower serum infliximab levels. These data confirm that ADAs are common with biologic therapy and significantly impact the efficacy of these drugs.